Immunotherapy for Cancer Treatment: What the Otolaryngologist Needs to Know (AMW)
2020 AAO-HNSF Annual Meeting & OTO Experience
Head and neck cancer (HNC) is a heterogeneous disease with advanced/recurrent disease having a poor prognosis with low survival rates. In recent years immunotherapy has shown promise as a new therapeutic pathway and Pembrolizumab has been approved as a first line agent in the treatment of recurrent or metastatic HNSCC. Targeted therapies, such as those for immune checkpoints of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1), have been the agents with the greatest therapeutic potential. Patients newly diagnosed with SCCHN, whether by general otolaryngologists or head and neck surgeons, are also inquiring about immunotherapy with increasing frequency. Having a fundamental understanding of immunotherapy, its current indications and future possibilities, can be useful for counseling patients. This panel, geared toward general otolaryngologist, head and neck surgeons and trainees, will provide an overview of basic immunotherapy principals, followed by more in-depth review of treatment outcomes of current immunotherapy agents, ongoing clinical trials, as well as potential future agents.
Credits
CME:1.0, MOC:1.0
Description
Head and neck cancer (HNC) is a heterogeneous disease with advanced/recurrent disease having a poor prognosis with low survival rates. In recent years immunotherapy has shown promise as a new therapeutic pathway and Pembrolizumab has been approved as a first line agent in the treatment of recurrent or metastatic HNSCC. Targeted therapies, such as those for immune checkpoints of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1), have been the agents with the greatest therapeutic potential. Patients newly diagnosed with SCCHN, whether by general otolaryngologists or head and neck surgeons, are also inquiring about immunotherapy with increasing frequency. Having a fundamental understanding of immunotherapy, its current indications and future possibilities, can be useful for counseling patients. This panel, geared toward general otolaryngologist, head and neck surgeons and trainees, will provide an overview of basic immunotherapy principals, followed by more in-depth review of treatment outcomes of current immunotherapy agents, ongoing clinical trials, as well as potential future agents.Learning Objectives: 1. Define the basic principles of cancer immunotherapy. 2. Describe immunotherapies currently being used for the treatment of head and neck cancer. 3. Review new and emerging immunotherapies for head and neck cancer.Faculty: Clint Allen, MD(Nothing to Disclose), Nicole Schmitt, MD(Nothing to Disclose), Larissa Sweeny, MD(Nothing to Disclose), Ravindra Uppaluri, MD, PhD(Consulting Fees: Myself, Merck Incorporated).
Courses in package:
